12 Oct Tyrosine Kinase Inhibitor Slows Progression of Idiopathic Pulmonary Fibrosis
Dr. Eric White
MedicalResearch.com Interview with:
Eric Stephen White MD
Associate Professor of Medicine and Director of Translational Interstitial Lung Disease Research, Pulmonary and Critical Care Medicine
University of Michigan Health System
Medical Research: What is the background for this study? What are the main findings?
Dr. White: The data presented at the European Respiratory Society (ERS) International Congress 2015 provide additional insights into OFEV® (nintedanib), including safety and efficacy over approximately two years. The results show no relevant changes in the safety and tolerability of OFEV. The results also suggest that treatment has a long-term effect (approximately two years) on slowing disease progression across both pivotal and open-label trials (as measured by annual rate of forced vital capacity [FVC] decline). This ongoing study, INPULSIS™-ON, which is an open-label extension trial, is important because Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease that may require ongoing treatment.
Medical Research: What should clinicians and patients take away from your report?
Dr. White: Follow-on, “real-world” studies like INPULSIS™-ON are important because they inform us about the longer-term safety and efficacy of OFEV. Idiopathic Pulmonary Fibrosis is a chronic disease that oftentimes requires long-term treatment. Evidence that OFEV maintains its clinical effect in the absence of any new safety signals provides me with more information to discuss with my patients considering treatment with OFEV.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. White: Advancing the science of this devastating disease through ongoing research of OFEV in Idiopathic Pulmonary Fibrosis patients is important because, due to its rarity, there is little public awareness of IPF, and a lack of understanding by many in the healthcare community about how to best recognize and treat the disease. Early diagnosis and proper care are critical to helping people treat their condition.
Citation:
European Respiratory Society 2015 presentation discussing
Beneficial effect and safety profile of OFEV (nintedanib) on Idiopathic Pulmonary Fibrosis
[wysija_form id=”5″]
Eric Stephen White MD (2015). Tyrosine Kinase Inhibitor Slows Progression of Idiopathic Pulmonary Fibrosis
Last Updated on October 13, 2015 by Marie Benz MD FAAD